Key result
This review discusses the differential diagnosis of pulmonary hypertension in HFpEF and examines current trial data on the potential benefit of targeted PAH therapies in these patients.
This review highlights the diagnostic challenges of differentiating PAH from PH due to left heart disease in HFpEF patients and discusses the potential role of PAH-targeted therapies in this population.
The most common cause of pulmonary hypertension (PH) due to left heart disease (LHD) was previously rheumatic mitral valve disease. However, with the disappearance of rheumatic fever and an aging population, nonvalvular LHD is now the most common cause of group 2 PH in the developed world. In this review, we examine the challenge of investigating patients who have PH and heart failure with preserved ejection fraction (HF-pEF), where differentiating between pulmonary arterial hypertension (PAH) and PH-LHD can be difficult, and also discuss the entity of combined precapillary and postcapillary PH. Given the proven efficacy of targeted therapy for the treatment of PAH, there is increasing interest in whether these treatments may benefit selected patients with PH associated with HF-pEF, and we review current trial data.
No takes yet. Share an insight, caveat, or question.
Hussain et al. (2016) conducted a review in Pulmonary hypertension and heart failure with preserved ejection fraction (HF-pEF). Targeted therapy for pulmonary arterial hypertension was evaluated. This review discusses the differential diagnosis of pulmonary hypertension in HFpEF and examines current trial data on the potential benefit of targeted PAH therapies in these patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: